Suppr超能文献

烷基化试剂耐药机制。

Mechanisms of resistance to alkylating agents.

机构信息

Department of Oncology, Instituto di Ricerche Farmacologiche 'Mario Negri', Via Eritrea 62, 20157, Milan, Italy.,

出版信息

Cytotechnology. 1998 Sep;27(1-3):165-73. doi: 10.1023/A:1008060720608.

Abstract

Alkylating agents are the most widely used anticancer drugs whose main target is the DNA, although how exactly the DNA lesions cause cell death is still not clear. The emergence of resistance to this class of drugs as well as to other antitumor agents is one of the major causes of failure of cancer treatment. This paper reviews some of the best characterized mechanisms of resistance to alkylating agents. Pre- and post-target mechanisms are recognized, the former able to limit the formation of lethal DNA adducts, and the latter enabling the cell to repair or tolerate the damage. The role in the pre-target mechanisms of reduced drug accumulation and the increased detoxification or activation systems (such as DT-diaphorase, metallothionein, GST/GSH system, etc...) are discussed. In the post-target mechanisms the different DNA repair pathways, tolerance to alkylation damage and the 'downstream' effects (cell cycle arrest and/or apoptosis) are examined.

摘要

烷化剂是应用最广泛的抗癌药物,其主要作用靶点是 DNA,尽管确切的 DNA 损伤如何导致细胞死亡尚不清楚。对这类药物以及其他抗肿瘤药物的耐药性的出现是癌症治疗失败的主要原因之一。本文综述了一些对烷化剂耐药性的特征性机制。目前已经认识到了靶前和靶后机制,前者能够限制致死性 DNA 加合物的形成,后者使细胞能够修复或耐受损伤。本文讨论了药物蓄积减少和解毒或激活系统(如 DT-黄递酶、金属硫蛋白、GST/GSH 系统等)增加在靶前机制中的作用。在后靶机制中,研究了不同的 DNA 修复途径、对烷化损伤的耐受性以及“下游”效应(细胞周期停滞和/或细胞凋亡)。

相似文献

1
Mechanisms of resistance to alkylating agents.
Cytotechnology. 1998 Sep;27(1-3):165-73. doi: 10.1023/A:1008060720608.
3
Contributions of DNA repair and damage response pathways to the non-linear genotoxic responses of alkylating agents.
Mutat Res Rev Mutat Res. 2016 Jan-Mar;767:77-91. doi: 10.1016/j.mrrev.2015.11.001. Epub 2015 Dec 2.
5
Alkylation damage in DNA and RNA--repair mechanisms and medical significance.
DNA Repair (Amst). 2004 Nov 2;3(11):1389-407. doi: 10.1016/j.dnarep.2004.05.004.
7
From old alkylating agents to new minor groove binders.
Crit Rev Oncol Hematol. 2014 Jan;89(1):43-61. doi: 10.1016/j.critrevonc.2013.07.006. Epub 2013 Aug 20.
8
Mechanisms of chemoresistance to alkylating agents in malignant glioma.
Clin Cancer Res. 2008 May 15;14(10):2900-8. doi: 10.1158/1078-0432.CCR-07-1719.
9
DNA alkylation damage and autophagy induction.
Mutat Res. 2013 Oct-Dec;753(2):91-99. doi: 10.1016/j.mrrev.2013.07.001. Epub 2013 Jul 18.

引用本文的文献

1
Protective Effects of L-Cysteine Against Cisplatin-Induced Oxidative Stress-Mediated Reproductive Damage.
Antioxidants (Basel). 2024 Nov 23;13(12):1443. doi: 10.3390/antiox13121443.
2
biofilm in inflammatory breast cancer and its treatment strategies.
Biofilm. 2024 Sep 13;8:100220. doi: 10.1016/j.bioflm.2024.100220. eCollection 2024 Dec.
3
Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents.
Neuro Oncol. 2024 Jun 3;26(6):1083-1096. doi: 10.1093/neuonc/noad252.
5
A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy.
Front Immunol. 2022 Jul 1;13:933547. doi: 10.3389/fimmu.2022.933547. eCollection 2022.
7
Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer.
Int J Mol Sci. 2022 Feb 6;23(3):1853. doi: 10.3390/ijms23031853.
8
Novel Marine Secondary Metabolites Worthy of Development as Anticancer Agents: A Review.
Molecules. 2021 Sep 23;26(19):5769. doi: 10.3390/molecules26195769.
9
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.
Front Cell Dev Biol. 2020 Sep 9;8:564601. doi: 10.3389/fcell.2020.564601. eCollection 2020.

本文引用的文献

2
DNA minor groove binding ligands: a new class of anticancer agents.
Expert Opin Investig Drugs. 1997 Jul;6(7):875-84. doi: 10.1517/13543784.6.7.875.
7
Apoptosis and the dilemma of cancer chemotherapy.
Blood. 1997 Mar 15;89(6):1845-53.
9
Characterization of a protein recognizing minor groove binders-damaged DNA.
Nucleic Acids Res. 1996 Nov 1;24(21):4227-33. doi: 10.1093/nar/24.21.4227.
10
DNA repair: enzymatic mechanisms and relevance to drug response.
J Natl Cancer Inst. 1996 Oct 2;88(19):1346-60. doi: 10.1093/jnci/88.19.1346.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验